European Trial of Beckman Coulter DxN Veris Shows Workflow Improvements for MDx Testing | GenomeWeb

NEW YORK (GenomeWeb) – A trial in the UK of Beckman Coulter's CE-marked molecular diagnostics system, the DxN Veris, has demonstrated enhancements to workflow and productivity.

In the analysis, published in the August issue of Pathology in Practice, laboratorians at the Department of Virology at Sheffield Teaching Hospitals NHS Foundation Trust examined the effect of consolidating four virology assays onto the DxN Veris.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.